>
Switch to:

Intellia Therapeutics PE Ratio

: At Loss (As of Today)
View and export this data going back to 2016. Start your Free Trial

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2022-05-28), Intellia Therapeutics's share price is $48.75. Intellia Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 was $-5.03. Therefore, Intellia Therapeutics's PE Ratio for today is At Loss.


The historical rank and industry rank for Intellia Therapeutics's PE Ratio or its related term are showing as below:

NTLA' s PE Ratio Range Over the Past 10 Years
Min: At Loss   Med: At Loss   Max: At Loss
Current: At Loss



NTLA's PE Ratio is ranked worse than
100% of 282 companies
in the Biotechnology industry
Industry Median: 28.36 vs NTLA: At Loss

Intellia Therapeutics's Earnings per Share (Diluted) for the three months ended in Mar. 2022 was $-1.96. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 was $-5.03.

As of today (2022-05-28), Intellia Therapeutics's share price is $48.75. Intellia Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2022 was $-5.03. Therefore, Intellia Therapeutics's PE Ratio without NRI for today is At Loss.

Intellia Therapeutics's EPS without NRI for the three months ended in Mar. 2022 was $-1.96. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2022 was $-5.03.

During the past 3 years, the average EPS without NRI Growth Rate was -24.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was -17.70% per year.

During the past 8 years, Intellia Therapeutics's highest 3-Year average EPS without NRI Growth Rate was -8.50% per year. The lowest was -41.40% per year. And the median was -19.10% per year.

Intellia Therapeutics's EPS (Basic) for the three months ended in Mar. 2022 was $-1.96. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2022 was $-5.03.


Intellia Therapeutics PE Ratio Historical Data

The historical data trend for Intellia Therapeutics's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intellia Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
PE Ratio
Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Intellia Therapeutics Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
PE Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison

For the Biotechnology subindustry, Intellia Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Intellia Therapeutics PE Ratio Distribution

For the Biotechnology industry and Healthcare sector, Intellia Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Intellia Therapeutics's PE Ratio falls into.



Intellia Therapeutics PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Intellia Therapeutics's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=48.75/-5.030
=At Loss

Intellia Therapeutics's Share Price of today is $48.75.
Intellia Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.03.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio or PE Ratio (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Intellia Therapeutics  (NAS:NTLA) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Intellia Therapeutics PE Ratio Related Terms

Thank you for viewing the detailed overview of Intellia Therapeutics's PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Intellia Therapeutics Business Description

Intellia Therapeutics logo
Industry
Healthcare » Biotechnology NAICS : 325413 SIC : 2835
Traded in Other Exchanges
Address
40 Erie Street, Suite 130, Cambridge, MA, USA, 02139
Intellia Therapeutics Inc is a genome editing company. It is focused on developing proprietary, potentially curative CRISPR/Cas9-based therapeutics. Its pipeline includes in vivo development programs targeting genetic diseases, including transthyretin amyloidosis and hereditary angioedema, and ex vivo programs which include Acute Myeloid Leukemia.
Executives
Rivera Jose E officer: EVP, General Counsel C/O INTELLIA THERAPEUTICS, INC. 40 ERIE STREET, SUITE 130 CAMBRIDGE MA 02139
Leonard John M director, officer: President and CEO C/O INTELLIA THERAPEUTICS INC 40 ERIE STREET, SUITE 130 CAMBRIDGE MA 02139
Crowley John F director C/O AMICUS THERAPEUTICS, INC. 1 CEDAR BROOK DRIVE CRANBURY NJ 08512
Dorsa Caroline director BIOGEN INC. 225 BINNEY ST. CAMBRIDGE MA 02142
Goodman Jesse director C/O INTELLIA THERAPEUTICS, INC. 40 ERIE STREET, SUITE 130 CAMBRIDGE MA 02139
Cohen Fred E director 301 COMMERCE STREET SUITE 3300 FORT WORTH TX 76102
Karsen Perry A director C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901
Verwiel Frank director C/O INTERMUNE, INC. 3280 BAYSHORE BLVD. BRISBANE CA 94005
Formela Jean Francois director C/O ATLAS VENTURE 890 WINTER STREET WALTHAM MA 02451
Lebwohl David officer: EVP, Chief Medical Officer C/O INTELLIA THERAPEUTICS, INC. 40 ERIE STREET, SUITE 130 CAMBRIDGE MA 02139
Goddard Glenn officer: EVP, Chief Financial Officer C/O AGIOS PHARMACEUTICALS, INC. 38 SIDNEY STREET, 2ND FLOOR CAMBRIDGE MA 02139
Sepp-lorenzino Laura officer: EVP, Chief Scientific Officer C/O INTELLIA THERAPEUTICS, INC. 40 ERIE STREET, SUITE 130 CAMBRIDGE MA 02139
Schiermeier Andrew officer: EVP, Chief Operating Officer C/O INTELLIA THERAPEUTICS 40 ERIE STREET STE 130 CAMBRIDGE MA 02139
Novartis Institutes For Biomedical Research, Inc. 10 percent owner 250 MASSACHUSETTS AVENUE CAMBRIDGE MA 02139
Novartis Ag 10 percent owner LICHTSTRASSE 35 BASEL V8 CH 4056

Intellia Therapeutics Headlines

From GuruFocus

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)